Winston K.C. Lam Joins Caris Life Sciences as Executive Vice President, Business Development and Chief Legal Officer

Winston K.C. Lam Joins Caris Life Sciences as Executive Vice President, Business Development and Chief Legal Officer


August 24, 2010 Caris Life Sciences(TM), Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest-quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, announced today that Winston K.C. Lam has joined the Company as Executive Vice President, Business Development and Chief Legal Officer. Lam assumes responsibility for Caris Life Sciences' business development, governmental affairs, legal strategy, and pharmaceutical services offering.

"Caris is extremely well-positioned to capitalize on several trends driving the healthcare market, including increasing partnerships and collaborations, as well as healthcare agenda-setting," said David D. Halbert, Chairman and Chief Executive Officer. "KC's legal acumen and business counsel will be invaluable, as we explore related opportunities both domestically and in global markets."

Lam brings 25 years of experience providing strategic business development direction and legal guidance to pharmaceutical, biopharmaceutical and medical device companies. He joins Caris Life Sciences from Schering-Plough Corporation, where he was most recently the Group Vice President & Associate General Counsel for the global pharmaceutical business. In Lam's five years at Schering-Plough, he led a team of 60 lawyers, supporting research & development, manufacturing, and worldwide commercial operations, while providing law support for all business development, licensing and alliance management activities.

Prior to Schering-Plough, he led business development functions at McKesson Corporation and Baxter Healthcare Corporation. Lam holds a bachelor of arts in history from Carleton College, a law degree from Cornell University and a master of business administration from the University of Chicago.

About Caris Life Sciences

Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing the Carisome(TM) platform, a proprietary, blood-based technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, operates laboratories in the Dallas, Phoenix and Boston metro areas and is entering the European markets through its first international location, in Switzerland. For more information, visit www.carislifesciences.com.


CONTACT: Caris Life Sciences Media Inquiries: Holly Clark 214-596-7060 [email protected]

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.